Assessing Safety of Direct Thrombin Inhibitors, Direct Factor Xa Inhibitors and Vitamin K Antagonists in Patients with Atrial Fibrillation: A Nation-Wide Propensity Score Matched Cohort from Sweden

References

• Friberg L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274(5):461–468. doi:10.1111/joim.1211423879838
   PubMedGoogle Scholar
• Lindberg T, Wimo A, Elmståhl S, Qiu C, Bohman DM, Sanmartin Berglund J. Prevalence and Incidence of Atrial Fibrillation and Other Arrhythmias in the General Older Population: Findings From the Swedish National Study on Aging and Care. Gerontol Geriatr Med. 2019;5:2333721419859687. Published 2019 Jun 27. doi:10.1177/2333721419859687
   Google Scholar
• Reddy P, Atay JK, Selbovitz LG, et al. Dabigatran: a review of clinical and pharmacoeconomic evidence. Crit Pathw Cardiol. 2011;10(3):117–127. doi:10.1097/HPC.0b013e3182315c0321989032
   PubMedGoogle Scholar
• Byon W, Garonzik S, Boyd RA, et al. Apixaban: a clinical pharmacokinetic and pharmacodynamic review. Clin Pharmacokinet. 2019;58(10):1265–1279. doi:10.1007/s40262-019-00775-z31089975
   PubMed Web of Science ®Google Scholar
• Kvasnicka T, Malikova I, Zenahlikova Z, et al. Rivaroxaban - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):636–642. doi:10.2174/138920021866617051816544328524005
   PubMed Web of Science ®Google Scholar
• Chen BC, Viny AD, Garlich FM, et al. Hemorrhagic complications associated with dabigatran use. Clin Toxicol. 2012;50(9):854–857. doi:10.3109/15563650.2012.721888
   Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131(2):157–164. doi:10.1161/CIRCULATIONAHA.114.01206125359164
   PubMed Web of Science ®Google Scholar
• Hernandez I, Baik SH, Piñera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175(1):18–24. doi:10.1001/jamainternmed.2014.539825365537
   PubMed Web of Science ®Google Scholar
• Wychowski MK, Kouides PA, et al. Dabigatran-induced gastrointestinal bleeding in an elderly patient with moderate renal impairment. Ann Pharmacother. 2012;46(4):608. doi:10.1345/aph.1Q747
   Google Scholar
• Chang HY, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. Br Med J. 2015;350(h1585):1–7. doi:10.1136/bmj.h1585
   Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Skjøth F, et al. Efficacy and safety of dabigatran etexilate and warfarin in “real-world” patients with atrial fibrillation: a prospective nationwide cohort study. J Am Coll Cardiol. 2013;61(22):2264–2273. doi:10.1016/j.jacc.2013.03.02023562920
   PubMed Web of Science ®Google Scholar
• Maura G, Blotière P-O, Bouillon K, et al. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation. 2015;132(13):1252–1260. doi:10.1161/CIRCULATIONAHA.115.01571026199338
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, Investigators RLSCa, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. doi:10.1056/NEJMoa0905561.19717844
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. doi:10.1056/NEJMoa110703921870978
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, Investigators. RA, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. doi:10.1056/NEJMoa1009638.21830957
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol. 2009;24(11):659–667. doi:10.1007/s10654-009-9350-y19504049
   PubMed Web of Science ®Google Scholar
• Ludvigsson JF, Andersson E, Ekbom A, et al. External review and validation of the Swedish national inpatient register. BMC Public Health. 2011;11(1):1–16. doi:10.1186/1471-2458-11-45021199570
   PubMed Web of Science ®Google Scholar
• Wettermark B, Hammar N, MichaelFored C, et al. The new Swedish Prescribed Drug Register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 2007;16(7):726–735. doi:10.1002/pds.129416897791
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology ON. DDD: definition and general considerations. Available from: https://www.whocc.no/ddd/definition_and_general_considera/. Accessed 226, 2020.
   Google Scholar
• Reducing PL Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques. Paper presented at: Twenty-Sixth Annual SAS Users Group International Conference, 2001; Long Beach, California.
   Google Scholar
• Signorello LB, McLaughlin JK, Lipworth L, et al. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9(3):199–205. doi:10.1097/00045391-200205000-0000511941379
   PubMedGoogle Scholar
• Southworth MR, Reichman ME, Unger EF, et al. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368(14):1272–1274. doi:10.1056/NEJMp130283423484796
   PubMed Web of Science ®Google Scholar
• Yen HW. Fatal nonvariceal gastrointestinal bleeding in a cirrhotic patient taking apixaban with no history of hemorrhage. Cureus. 2019;11(11):e6126.31886064
   PubMed Web of Science ®Google Scholar
• Lakatos B, et al. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Med Wkly. 2014;144:w13906.24452338
   PubMed Web of Science ®Google Scholar
• Holster IL, Valkhoff VE, Kuipers EJ, et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology. 2013;145(1):105–112. doi:10.1053/j.gastro.2013.02.04123470618
   PubMed Web of Science ®Google Scholar
• Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. Br Med J. 2015;350(h1857):1–9. doi:10.1136/bmj.h1857
   Web of Science ®Google Scholar
• Staerk L, Gislason GH, Lip GYH, et al. Risk of gastrointestinal adverse effects of dabigatran compared with warfarin among patients with atrial fibrillation: a nationwide cohort study. Europace. 2015;17(8):1215–1222. doi:10.1093/europace/euv11925995392
   PubMed Web of Science ®Google Scholar
• Alotaibi GS, Almodaimegh H, McMurtry MS, et al. Do women bleed more than men when prescribed novel oral anticoagulants for venous thromboembolism? A sex-based meta-analysis. Thromb Res. 2013;132(2):185–189. doi:10.1016/j.thromres.2013.07.01723932014
   PubMed Web of Science ®Google Scholar
• Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. BMJ Open. 2013;3(5):1–9. doi:10.1136/bmjopen-2013-002758
   Web of Science ®Google Scholar
• Ezekowitz MD, Wallentin L, Connolly SJ, Investigators RLSCa, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122(22):2246–2253. doi:10.1161/CIRCULATIONAHA.110.973735.21147728
   PubMed Web of Science ®Google Scholar
• Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127(7):650–656. doi:10.1016/j.amjmed.2014.01.03124530792
   PubMed Web of Science ®Google Scholar
• Nathan KT, Conn KM, van Manen RP, et al. Signal detection for bleeding associated with the use of direct oral anticoagulants. Am J Health Syst Pharm. 2018;75(13):973–977. doi:10.2146/ajhp17052929735612
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363–2372. doi:10.1161/CIRCULATIONAHA.110.00474721576658
   PubMed Web of Science ®Google Scholar
• Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients. Int J Cardiol. 2013;167(4):1237–1241. doi:10.1016/j.ijcard.2012.03.14822494863
   PubMed Web of Science ®Google Scholar
• Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J. 2011;32(18):2282–2290. doi:10.1093/eurheartj/ehr13421616951
   PubMed Web of Science ®Google Scholar
• Singer DE, Hellkamp AS, Piccini JP, et al. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc. 2013;2(1):e000067. doi:10.1161/JAHA.112.00006723525418
   PubMed Web of Science ®Google Scholar
• Forslund T, Wettermark B, Wändell P, et al. Risk scoring and thromboprophylactic treatment of patients with atrial fibrillation with and without access to primary healthcare data: experience from the Stockholm health care system. Int J Cardiol. 2013;170(2):208–214. doi:10.1016/j.ijcard.2013.10.06324239153
   PubMed Web of Science ®Google Scholar
• Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342(jan31 1):1–9. doi:10.1136/bmj.d124
   Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Dabigatran and warfarin for secondary prevention of stroke in atrial fibrillation patients: a nationwide cohort study. Am J Med. 2014;127(12):1172–8.e5. doi:10.1016/j.amjmed.2014.07.02325193361
   PubMed Web of Science ®Google Scholar